To demonstrate the efficacy of BVC against ovarian cancer, researchers developed innovative mesoporous silica nanoparticles (MSN) coupled to tumour endothelial marker 1 (TEM1)/endosialin (Ab-/scFv). Here, CD248 is linked to ovarian carcinoma.